Published in
Elsevier, The Lancet Oncology, 3(24), p. 297-306, 2023
DOI: 10.1016/s1470-2045(23)00001-3
Links
Tools
Bevacizumab plus FOLFIRI after failure of platinum–etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial
Journal article published in 2023 by
Thomas Walter 
,
Astrid Lievre,
Romain Coriat,
David Malka,
Farid Elhajbi,
Fréderic Di Fiore,
Olivia Hentic,
Denis Smith,
Vincent Hautefeuille,
Guillaume Roquin,
Marine Perrier,
Laetitia Dahan,
Victoire Granger,
Iradj Sobhani,
Laurent Mineur
and other authors.
,
Astrid Lievre,
Romain Coriat,
David Malka,
Farid Elhajbi,
Fréderic Di Fiore,
Olivia Hentic,
Denis Smith,
Vincent Hautefeuille,
Guillaume Roquin,
Marine Perrier,
Laetitia Dahan,
Victoire Granger,
Iradj Sobhani,
Laurent Mineur
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 